![]() |
|
||||
| Degree: | BSc Chemistry |
| Institution: | University of Victoria |
| Period: | 1987 |
| Degree: | PhD |
| Institution: | University of British Columbia |
| Period: | 1993 |
| Position: | Associate Professor |
| Institution: | Universiti Malaysia Sarawak, Kuching, Sarawak, Malaysia |
| Period: | 1998 - 2002 |
| Position: | Senior Scientist |
| Institution: | Advanced Therapeutics, BC Cancer Agency |
| Position: | Adjunct Professor |
| Institution: | Division of Pharmaceutics and Biopharmaceutics, Faculty of Pharmacy, University of British Columbia |
| Name: | Chevening Scholar |
| Period: | 2001 |
| Name: | Rethink Breast Cancer Scientist |
| Period: | 2005-2010 |
Our group uses non-invasive imaging techniques to examine changes in tumour physiology following treatment response or disease progression in preclinical models for various solid cancers. The focus of our research is to understand what happens to tumour parameters such as metabolism, blood flow and oxygen levels during treatments, and potentially use these as markers to predict or monitor how a patient responds to a particular treatment. Our research collaborations with basic scientists and clinicians are translational in nature and the ultimate goal is to have an impact on patient care.
We operate in a multi-disciplinary setting and use in vitro and in vivo methods in conjunction with imaging and classical molecular techniques to study tumours at all levels – genetic, cellular and also in situ, tissue level. Trainees are encouraged to explore all sides of a research problem and to respond with solutions that are clinically relevant.
Primary human tumours are used to examine the effects of experimental therapeutics that target the vasculature and/or change vascular function. Changes in tumour physiology secondary to modified vascular function are then used as markers or to plan a sequential series of treatments that take advantage of the attenuated tumour microenvironment.
The effects of overexpressing HER-2/neu on tumour metabolism are being examined to identify novel therapeutic targets in HER-2 positive breast cancer.
Our group is working closely with MDS-Nordion to develop biological targeting agents for Positron Emission Tomography using Cu-64 or Ga-68.
|
« Back